NCT02890758View on ClinicalTrials.gov

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

June 1, 2021

Study Completion Date

February 17, 2023

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Lymphoblastic LeukemiaChronic Myeloid LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin LymphomaHodgkin LymphomaMyeloproliferative SyndromesPlasma Cell MyelomaColon CarcinomaAdenocarcinoma of RectumSoft Tissue SarcomaEwing's SarcomaRhabdomyosarcoma
Interventions
BIOLOGICAL

Natural Killer (NK) Cells

Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT

BIOLOGICAL

ALT803

given at 6mcg/kg weekly for four weeks

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Brenda Cooper, MD

OTHER

NCT02890758 - Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Biotech Hunter | Biotech Hunter